What do systematic reviews say?

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1042 participants
  Very low

Summary of findings: insulin degludec vs insulin glargine

Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.22 [0.82, 1.82]
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.39 [0.59, 3.27]
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.92 [0.58, 1.46]
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1388 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

The review found no eligible studies for this question.

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs Insulin glargin (control)

The review found no eligible studies for this question.

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs Insulin glargin (control)

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2250 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one severe hypoglycaemic… compared with insulin glargin (control) (low certainty).

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  RR 0.82 [0.51, 1.32]
  4 studies · 2252 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one hypoglycaemic event compared with insulin glargin (control) (low certainty).

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  RR 0.98 [0.92, 1.05]
  4 studies · 2252 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2250 participants
  High

Summary of findings: insulin detemir vs Insulin glargin (control)

Insulin detemir (intervention) may leads to higher percentage of participants having at least one injection site reaction compared with insulin glargin (control) (low certainty).

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  RR 3.31 [1.13, 9.73]
  4 studies · 2252 participants
  Low

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: NPH insulin vs insulin glargine

It is very uncertain whether summary of findings: NPH insulin changes hypoglycemia mean number of events per participant compared with glargine (very low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

DPP‐4 inhibitors vs insulin glargine

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs insulin glargine

The review found no eligible studies for this question.

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found